Law360, New York (May 3, 2017, 8:11 PM EDT) -- Six generic-drug makers accused of conspiring to fix the prices of an antibiotic and a diabetes medication have asked a Connecticut federal court to toss the suit now joined by 40 states, saying the complaint contains a multitude of legal flaws.
Heritage Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc. and others on Monday filed a joint motion to dismiss the amended complaint, which 20 additional states signed on to. The drugmakers are accused of illegally conspiring to divvy up the market for doxycycline hyclate delayed release, an antibiotic used to treat respiratory infections, and glyburide, an oral diabetes medication,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!